bitFlyer Makes Cryptocurrency Trading Even Easier with Launch of bitFlyer App
21.10.2019 08:00:00 EEST | Business Wire | Press release
Today, leading cryptocurrency exchange bitFlyer has announced the launch of the bitFlyer app across Europe and the USA. The app, available for free on both iOS and Android, will allow users to buy and sell Bitcoin (BTC), Ethereum (ETH), Litecoin (LTC), Bitcoin Cash (BCH), Ethereum Classic (ETC), Monacoin (MONA) and Lisk (LSK).1
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191020005009/en/
bitFlyer app iOS
The bitFlyer app will make it even easier for users to buy and sell, whilst still adhering to the same robust KYC and verification standards as the bitFlyer website.
Since 2014, bitFlyer has been trusted by millions across the globe as the most secure platform to easily buy and sell cryptocurrencies, and remains the only exchange licensed to operate across the US, Japan and Europe combined. This app launch is the latest development in a major growth strategy by the European and US businesses, to match what is already available to millions of bitFlyer Japan customers, where bitFlyer is recognised as a household name and one of the longest-standing cryptocurrency exchanges.
Yuzo Kano, bitFlyer founder and CEO of bitFlyer USA, said: “With the new bitFlyer apps, we are bringing the reliability, security and experience of Japan's market leader to our European and American customers, closing the gap between our service offerings and creating a truly global and regulated exchange product.”
Andy Bryant, Co-head and COO at bitFlyer Europe, said: “With our Buy/Sell platform, we strived to create a simpler, faster and even more transparent experience where everyone can buy cryptocurrencies in just a few minutes and from a reputable source. Now with the bitFlyer app, this is even more convenient for users.
We are staying true to our mission of making the world simpler with blockchain, by making the transparency, security and simplicity of our robust trading platforms available via a quick, single app download.”
Buy instantly and securely
The bitFlyer app was created with users in mind, making it even easier for those who prefer navigating from a smartphone to buy and sell cryptocurrencies. Current bitFlyer users can log on to the app with their existing account details, while new traders can register by using an email address, and inputting the relevant information for KYC procedures to deposit and begin trading.
Other features of the bitFlyer app include:
● Users are shown real-time price data, notified about the latest market movements and given access to the latest cryptocurrency news without leaving the app, encouraging users to always stay on top of the market and make informed decisions
● Users can clearly follow their position, making it even easier to keep track of profit and loss (PnL), view trade history and seamlessly visualise their portfolio
● Users can now simply scan a QR code to send and receive virtual currencies with bitFlyer
● From October 21st to October 27th, new customers downloading the bitFlyer app and registering a new verified account will receive €10 (or $10 if based in the US) in BTC without any deposit required.
Key features:
● Buy Bitcoin, Ethereum, Litecoin and more in just a few taps using USD, EUR, or JPY 2
● See real-time price data and get notified about market movements
● Added news functionality allows users to access the latest industry news without leaving the app
bitFlyer launched in the USA in November 2017, followed by bitFlyer Europe in January 2018, both as fully owned subsidiaries of bitFlyer, Inc., a household name in the cryptocurrency space in Japan and one of the longest-standing cryptocurrency exchanges. It is the only cryptocurrency exchange to be licenced in Japan, the US and Europe combined, and has also recently been recognised as one of only 10 exchanges that isn’t faking trading volumes.
bitFlyer is passionate about the future of the cryptocurrency industry and aims to support that future by setting the global standard for exchanges. It believes that standards and regulations are fundamental to the future of the industry and is often involved in conversations at the highest level, including having taken part in the recent G20 discussions. It was also involved in the amendment to the Payments Act in Japan which famously recognised bitcoin as legal tender.
The company continues to build out its product portfolio in line with its vision to break down barriers of entry that many face while accessing cryptocurrency. bitFlyer Japan already offers a wide range of products, and the addition of new Apps in the US and EU is the beginning of the brand’s ambition to expand access to cryptocurrency on a global scale.
ENDS
About bitFlyer EUROPE S.A.
bitFlyer EUROPE S.A. is a wholly-owned subsidiary of bitFlyer, Inc., a leading bitcoin and blockchain company based in Japan. The European office is located in Luxembourg and operates an exchange platform for European traders to buy and sell cryptocurrencies. bitFlyer EUROPE S.A. site: https://bitflyer.com/en-eu/
About bitFlyer USA, Inc.
bitFlyer USA, Inc. is a wholly-owned subsidiary of bitFlyer, Inc., a leading Bitcoin and blockchain company based in Japan. The US office is located in San Francisco and operates an exchange platform for US traders to buy and sell cryptocurrencies. Launching in the U.S. in 2017, bitFlyer USA currently operates in 46 states and territories, including New York as a holder of the New York Bitlicense. bitFlyer USA, Inc., site: https://bitflyer.com/en-us/
1MONA and LSK available in Europe and Japan only.
2 Depending on jurisdiction
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191020005009/en/
Contact information
Lauren Armour
Tyto PR
07826 557 326
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom